• KOLs Community
    • Myelodysplastic
    • Myelodysplastic Syndromes
    • Alan Francis List
    • Alan Francis List

      Alan Francis List

      Precision BioSciences Durham, NC, United States | Precision BioSciences, Inc., Raleigh, North Carolina, United States. | Malignant Hematology Department, H. Lee Moffitt Cancer ...



      KOL Resume for Alan Francis List


      Precision BioSciences Durham, NC, United States


      Malignant Hematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

      Clinical Science, Precision BioSciences (United States)

      Precision BioSciences, Inc., Durham, NC


      H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

      Department of Hematologic Malignancies, Moffitt Cancer Center, Tampa, FL;


      Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

      Moffitt Cancer Center, Tampa, Florida.


      MD Moffitt Cancer Center and Research Institute, Tampa, FL.

      H. Lee Moffitt Cancer Center, Tampa, FL

      Lee Moffitt Cancer Center Research Institute, Malignant Hematology


      Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

      H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA


      Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL,

      H. Lee Moffitt Cancer Center & Research Institute


      Moffitt Cancer Center, Tampa, FL 33612;

      Dept. of Oncologic Sciences, University of South Florida, Morsani College of Medicine, Tampa, FL

      Department of Oncologic Sciences, University of South Florida, Tampa, Florida.


      Moffitt Cancer Center, Tampa, FL (A.L.).



      Alan Francis List: Influence Statistics

      Sample of concepts for which Alan Francis List is among the top experts in the world.
      Concept World rank
      aml ipss #1
      burden mds #1
      nbm aml patients #1
      mds specimens #1
      lenalidomide hematologic activity #1
      karyotypic abnormalities patients #1
      promyelocytes levels #1
      treatment rraml #1
      mds eltrombopag #1
      azanucleoside failure patients #1
      del5q haploinsufficiency #1
      dock4 proteins #1
      costs lenalidomide therapy #1
      5q del5q #1
      promotes erythropoiesis #1
      p53 erythroid precursors #1
      mds tumor necrosis #1
      del5q aml #1
      runx1mut aml aml #1
      granulocyte differentiation patients #1
      dock4 loss #1
      mds nlrp3 #1
      lenalidomidespecific #1
      trend atg #1
      atg mds #1
      95 eversmokers #1
      serial molecular #1
      membrane raft dependent #1
      conserved physiologic function #1
      pgp myeloid #1
      phosphatase haplodeficiency #1
      3 abnormalities #1
      myeloid neoplasms antimetabolites #1
      prevalence aid #1
      2 cmml #1
      bone marrow hypocellularity #1
      aza treatment patients #1
      myelodysplasia myc #1
      epo 1 year #1
      patients mds cases #1
      mds mdsc #1
      category median #1
      del5q responses #1
      p53 expression erythropoiesis #1
      aml runx1wt #1
      azacitidine therapy illness #1
      leukemia progression patients #1
      syndromes abstract #1
      induction chemotherapy cytarabine #1


      Prominent publications by Alan Francis List

      KOL-Index: 18609

      Dasatinib (BMS-354825) is a novel, oral, potent, multi-targeted kinase inhibitor of Bcr-Abl and Src family kinases (SFK) and is a promising cancer therapeutic agent. Preclinical data indicate that dasatinib is 325-fold more potent than imatinib against cells expressing wild-type Bcr-Abl, and that dasatinib is active against 18 of 19 Bcr-Abl mutations known to cause imatinib resistance. Phase I clinical data show that dasatinib is well tolerated and highly effective for the treatment of ...

      Known for Leukemia Cells | Stat5 Signaling | Chronic Myelogenous | Apoptosis Dasatinib | Imatinib Resistance
      KOL-Index: 17644

      Chronic myelomonocytic leukemia is a heterogeneous disease with multifactorial molecular pathogenesis. Various recurrent somatic mutations have been detected alone or in combination in chronic myelomonocytic leukemia. Recently, recurrent mutations in spliceosomal genes have been discovered. We investigated the contribution of U2AF1, SRSF2 and SF3B1 mutations in the pathogenesis of chronic myelomonocytic leukemia and closely related diseases. We genotyped a cohort of patients with chronic ...

      Known for Chronic Myelomonocytic Leukemia | U2af1 Srsf2 | Spliceosomal Genes | Somatic Mutations | Juvenile Myelomonocytic
      KOL-Index: 16226

      Vascular endothelial growth factor (VEGF) is a potent angiogenic peptide with biologic effects that include regulation of hematopoietic stem cell development, extracellular matrix remodeling, and inflammatory cytokine generation. To delineate the potential role of VEGF in patients with myelodysplastic syndrome (MDS), VEGF protein and receptor expression and its functional significance in MDS bone marrow (BM) were evaluated. In BM clot sections from normal donors, low-intensity ...

      Known for Cell Growth | Vascular Endothelial | Mds Vegf | Myelodysplastic Syndromes | Myeloid Precursors
      KOL-Index: 15633

      BACKGROUND: Clonal haemopoiesis of indeterminate potential (CHIP) is an age-associated genetic event linked to increased risk of primary haematological malignancies and increased all-cause mortality, but the prevalence of CHIP in patients who develop therapy-related myeloid neoplasms is unknown. We did this study to investigate whether chemotherapy-treated patients with cancer who have CHIP are at increased risk of developing therapy-related myeloid neoplasms.

      METHODS: We did a nested, ...

      Known for Chip Patients | Therapy Myeloid | Clonal Haemopoiesis | Neoplasms Primary | Allele Frequency
      KOL-Index: 14435

      Even though myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis, the molecular alterations that lead to marrow failure have not been well elucidated. We have previously shown that the myelosuppressive TGF-β pathway is constitutively activated in MDS progenitors. Because there is conflicting data about upregulation of extracellular TGF-β levels in MDS, we wanted to determine the molecular basis of TGF-β pathway overactivation and consequent hematopoietic ...

      Known for Β Receptor | Hematopoietic Cells | Myelodysplastic Syndromes Mds | Ineffective Hematopoiesis | Smad7 Protein
      KOL-Index: 13960

      OBJECTIVE: Vascular endothelial growth factor (VEGF) interacts with two high-affinity receptor tyrosine kinases (RTK) on vascular endothelium to initiate complementary but disparate biologic responses. We previously reported that acute myeloid leukemia (AML) cells express VEGF and one or both VEGF-A receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2). To evaluate receptor-selective trophic response to VEGF-A in AML cells, we investigated receptor-specific ligand activation responsible for ...

      Known for Growth Factor | Vascular Endothelial | Acute Myeloid | Leukemia Cells | Vegf Vegfr1
      KOL-Index: 13720

      Single nucleotide polymorphism arrays (SNP-As) have emerged as an important tool in the identification of chromosomal defects undetected by metaphase cytogenetics (MC) in hematologic cancers, offering superior resolution of unbalanced chromosomal defects and acquired copy-neutral loss of heterozygosity. Myelodysplastic syndromes (MDSs) and related cancers share recurrent chromosomal defects and molecular lesions that predict outcomes. We hypothesized that combining SNP-A and MC could ...

      Known for Myeloid Malignancies | Snp Array | Myelodysplastic Syndromes | Chromosome Aberrations | Prognostic Impact
      KOL-Index: 13616

      BACKGROUND: Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival compared with the three commonest conventional care regimens.

      METHODS: In a phase III, international, multicentre, controlled, parallel-group, open-label trial, patients with higher-risk myelodysplastic syndromes were randomly assigned one-to-one to receive azacitidine (75 mg/m(2) per day for 7 ...

      Known for Patients Azacitidine | Myelodysplastic Syndromes | Conventional Regimens | Phase Iii Study | Treatment Survival
      KOL-Index: 13465

      Purpose Azacitidine is standard, first-line therapy in higher-risk myelodysplastic syndromes (MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce superior overall response rates (ORRs) to azacitidine is not known. Patients and Methods North American Intergroup Study S1117 is a phase II/III trial that randomly assigned patients with higher-risk MDS and chronic myelomonocytic leukemia (CMML) 1:1:1 to azacitidine (75 mg/m2/day on days 1 to 7 of a 28-day ...

      Known for Chronic Myelomonocytic Leukemia | Azacitidine Patients | Risk Myelodysplastic | Randomized Phase | 75 Day
      KOL-Index: 13361

      PURPOSE: In a phase III randomized trial, azacitidine significantly prolonged overall survival (OS) compared with conventional care regimens (CCRs) in patients with intermediate-2- and high-risk myelodysplastic syndromes. Approximately one third of these patients were classified as having acute myeloid leukemia (AML) under current WHO criteria. This analysis compared the effects of azacitidine versus CCR on OS in this subgroup.

      PATIENTS AND METHODS: Patients were randomly assigned to ...

      Known for Ccr Patients | Survival Compared | Blast Count | Bone Marrow | Acute Myeloid

      Key People For Myelodysplastic Syndromes

      Top KOLs in the world
      John M Bennett
      myelodysplastic syndromes acute myeloid leukemia bone marrow
      Pierre Fenaux
      myelodysplastic syndromes honoraria funding board directors
      Ghulam J Mufti
      myelodysplastic syndromes honoraria funding speakers bureau
      Peter L Greenberg
      myelodysplastic syndromes mds patients consultancy funding
      Guillermo Francisco Sanz;
      myelodysplastic syndromes honoraria funding board directors
      Hagop Meguerditch Kantarjian
      consultancy funding board directors advisory committees

      Alan Francis List:Expert Impact

      Concepts for whichAlan Francis Listhas direct influence:Myelodysplastic syndromes,  Myelodysplastic syndrome,  Mds patients,  Acute myeloid leukemia,  Chronic myelomonocytic leukemia,  Myelodysplastic syndromes mds,  Patients mds,  Speakers bureau.

      Alan Francis List:KOL impact

      Concepts related to the work of other authors for whichfor which Alan Francis List has influence:Myelodysplastic syndromes,  Acute myeloid leukemia,  Bone marrow,  Stem cell,  Mds patients,  Multiple myeloma,  Multidrug resistance.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Precision BioSciences Durham, NC, United States | Precision BioSciences, Inc., Raleigh, North Carolina, United States. | Malignant Hematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL | Malignant Hematology, H Lee Mof

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.